Brain Cancer and Immunotherapy

October 7, 2021, 4:30 pm -
5:00 pm
New and emerging treatments

Watch On Demand

Session Description

Globally, approximately 300,000 men and women are diagnosed with a cancer of the brain and nervous system every year. Although significant advances have been made in understanding the biology of these cancers, the mortality rate has remained steady for more than 30 years. Immunotherapy offers potential new treatment options for this devastating set of diseases. Join Dr. David Reardon, director of Dana-Farber Cancer Institute’s Center for Neuro-Oncology, to discover new targeted therapies, immunomodulators, cancer vaccines, cell therapies, and oncolytic virus therapies currently approved or being explored in clinical trials. Don’t miss the opportunity to ask this leader in neuro-immunotherapeutics your questions.


David Reardon, M.D.

Dana-Farber Cancer Institute

Dr. David Reardon is a professor of medicine at Harvard Medical School and currently serves as the director of Dana-Farber Cancer Institute’s Center for Neuro-Oncology. He previously served as the associate deputy director of the Duke University Medical Center’s Preston Robert Tisch Brain Tumor Center for 11 years. He is an active researcher with special interests in the design and implementation of clinical trials for individuals with brain and spinal tumors, focusing particularly on immunotherapeutics. He has also led investigations of molecular-targeting agents, anti-angiogenic reagents, cytotoxins, and other biologically-based therapies. Dr. Reardon has published over 290 peer-reviewed manuscripts. He has received the R. Wayne Rundles Award for Excellence in Cancer Research as well as the Award for Excellence in Adult Clinical Research by the Society for Neuro-Oncology in 2015 and 2016. He served as the tenth president of the Society for Neuro-Oncology from 2013-2015.

On-Demand Now Available

We are excited to announce that videos from our 2021 Cancer Research Institute (CRI) Virtual Immunotherapy Patient Summit are now available to view on demand.

The on-demand videos can be found on each session page from the agenda.